FLOW Trial Journal Club
The New England Journal of Medicine published the FLOW trial in May 2024. This post is a journal club breaking down the FLOW trial and what change it may bring to our clinical practice.
Link to the trial on NEJM: https://www.nejm.org/doi/full/10.1056/NEJMoa2403347Background/Overview
Title: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
Citation: Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. NEJM May 2024;391(2):109-121.
Objective: To assess the efficacy and safety of subcutaneous semaglutide 1.0 mg once weekly for the prevention of kidney failure, substantial loss of kidney function, and death from kidney-related or cardiovascular causes in patients with type 2 diabetes and chronic kidney disease.
Primary Efficacy Measure: Major kidney disease events, a composite of:
- onset of kidney failure (initiation of long-term dialysis, kidney transplantation, or a reduction in the eGFR to <15 ml/min/1.73 m2 sustained for ≥28 days)
- a sustained (≥28 days) 50% or greater reduction in eGFR from baseline, or
- death from kidney-related or cardiovascular causes